While breast cancer has the mammogram and prostate cancer has the PSA, lung cancer does not have an equivalent test for detection. The National Cancer Institute (NCI) identifies chest x-rays, CT scans, PET scans and the bronchoscopy as tests used to diagnose lung cancer, but these tests are only effective after a patient has presented worsening respiratory symptoms.

Patients with mesothelioma often have symptoms such as a persistent cough, shortness of breath, fatigue and wheezing, similar to other respiratory illnesses. Typically, when a patient first exhibits these symptoms, doctors first treat them for a respiratory infection. They only test for cancer later. This leads to a late diagnosis, when the disease is already causing life-threatening complications.

Studies are underway to find an effective lung cancer and mesothelioma screening tool. Some researchers have developed tests to detect circulating tumor cells. Other tests include Cornell’s “glowing dots” that would attach to cancer cells and glow during a PET scan, and an electronic nose to detect mesothelioma in an exhaled breath.

There is hope that someday soon research will catch up with the dire need of future mesothelioma sufferers for early detection.

Cappolino Dodd Krebs, LLP – mesothelioma attorneys

In America, occupational asbestos exposure usually indicates experience in the construction business or shipyard workers. However, this article shows that asbestos exposure in the textile industry continues to be a problem. Thankfully, use of asbestos in American textile factories has largely ended, but we must continue to be diligent in making others aware of the harmful effects of asbestos exposure.

Cappolino Dodd Krebs LLP–Mesothelioma attorneys

According to Mesothelioma Help, however, one oncologist states that the drug shortages result from pharmaceutical companies who wish to increase their profit margins by focusing on drugs that will make more money. The American Society of Health-System Pharmacists (ASHP) wants to protect those suffering from mesothelioma who may not be able to receive their treatments due to drug shortages by pushing a bill that would require drug companies to tell the FDA when making changes to drug production.

Obviously, there is still more work to be done. A Drug Shortages Summit in 2010 looked at developing plans to stop disruptions in patient care caused by drug shortages and shedding light on the harm that the shortages cause patients. The summit also presented the possibility of providing incentives to drug companies that produce important products, such as mesothelioma drugs, so that there would be safeguards against shortages or even discontinuance. The fight against deadly cancers such as mesothelioma can only move on with patients’ continued access to medications they need to survive.

Cappolino Dodd Krebs LLP–Mesothelioma attorneys

According to the suit, Gipson smoked cigarettes from 1960 until 1995 and was a member of the United States Army from 1948 until 1951. Gipson and his wife are seeking a jury trial to resolve all issues involved. A Mesothelioma lawyer can answer your questions if you have been exposed to toxic asbestos fibers during your employment.

The couple is suing the following defendants upon theories of negligence, contaminated buildings, breach of express/implied warranty, strict liability, intentional tort, conspiracy, misrepresentation and post-sale duty to warn:

3M Company; A.O. Smith Corporation; A.W. Chesterton Company; Ashland Oil, Inc.; Aurora Pump Company; Brand Insulations, Inc.; BW IP, Inc.; Certainteed Corporation; Chicago Pump Company; Cleaver-Brooks Company, Inc.; Crane Co.; Dravo Corporation; Eaton Electrical, Inc.; Flowserve FSD Corporation; Flowserve US, Inc.; Foster Wheeler Energy Corporation; FMC Corporation; Gardner Denver, Inc.; General Electric Company; Goulds Pumps, Inc.; Grinnell Corporation; Honeywell International; Honeywell, Inc.; Howden North America, Inc.; IMO Industries, Inc.; Industrial Holdings Corporation; Ingersoll-Rand Company; ITT Corporation; Lockheed Martin Corporation; McJunkin Corporation; Metropolitan Life Insurance Company; Nagle Pumps, Inc.; Nitro Industrial Coverings, Inc.; Ohio Valley Insulating Company, Inc.; Owens-Illinois, Inc.; Pneumo Abex Corporation; Rapid American Corporation; Riley Stoker Corporation; Rockwell Automation, Inc.; Roper Pump Company; Rust International, Inc.; Square D Company; State Electric Supply Company; Sterling Fluid Systems (USA), LLC; Stockham Valves & Fittings; Taco, Inc.; Tasco Insulations, Inc.; Trane U.S. Inc.; UB West Virginia, Inc.; Uniroyal, Inc.; United Engineers & Constructors, Inc.; Viacom, Inc.; Viad Corporation; Vimasco Corporation; WABCO Company; West Virginia Electric Supply Company; and Zurn Industries, LLC.

The EPA estimates that 20,000 lung cancer deaths each year are radon-related. Radon is a form of ionizing radiation and is a proven carcinogen. Approximately 85% of radon-induced lung cancer patients die within 4-5 years of diagnosis.

Two studies have shown definite evidence of association between residential radon exposure and lung cancer. One study in North America combined data from several previous residential studies. Both studies confirmed the radon health risks predicted by occupational studies of underground miners who breathed radon for several years. Some researchers had questioned earlier whether occupational studies could be used to calculate risks from exposure to exposure to radon in the home environment.

The EPA’s former director of Indoor Environment Division said that the studies’ findings effectively end doubt about the risks of having radon in the home. Breathing even low levels of radon could lead to lung cancer, said Tom Kelly.

Dr. Michael Repacholi, coordinator of WHO’s Radiation and Environmental Health Unit said that radon poses a health risk to populations all over the world, but that the risk can be reduced. While radon health risks have received widespread attention, the carcinogen is the main source of exposure to ionizing radiation, and accounts to 50% of the public’s exposure to naturally-occurring sources of radiation, said Repacholi.

According to the doctor, one third of heavy smokers develop lung cancer. Research has shown that 15 to 20 out of every 100 patients diagnosed with lung cancer have had the bad habit most of their lives. Second hand smoke has lead to some of the diagnosis, while for some the cause is unknown.

Brawley cautions that smoking causes other health issues and not just lung cancer. The bad habit is known to cause 14 different cancers, including those of the head, neck, stomach, kidney, esophagus, pancreas, and bladder. It may also be linked to leukemia, ulcers, high blood pressure, diabetes, bronchitis, emphysema, osteoporosis and reproductive disorders.

A recent study has found that smokers of mentholated cigarettes are no more likely to develop lung cancer than other smokers. In fact, menthol smokers had a lower risk of developing lung cancer, according to a study published in the journal of the National Cancer Institute. The study found that mentholated cigarette smokers were about 12 times more likely to develop lung cancer, while non-menthol smokers had a 21 times the risk of developing the disease.

In the first study conducted by the group, a 39-year-old female patient with leukemia had her genome sequenced which lead to a change in treatment. The sequencing showed doctors a novel genetic error which doctors used to recommend targeted chemotherapy instead of a cell transplant. The patient is now in remission after successful chemotherapy treatment. The patient’s oncologist said that sequencing the genome offered the doctors an opportunity to make the correct call in recommending further therapy instead of a significantly risky stem cell transplant.

The second study conducted by the same group sequenced the genome of a deceased 42-year old female patient who had developed breast and ovarian cancer. The sequence detected a new mutation in a gene known to considerably raise the risk of cancer. Her family was informed and subsequently advised to receive genetic counseling, which resulted in findings that the patient’s three offspring are at high risk of developing cancer early on in life.

Genome sequencing could make a major difference in the lives of many cancer patients and their families. Both studies showed value in using genome sequencing as a diagnostic tool and perhaps even a cancer prevention method.

Rachel Dear, MD and lead researcher of the study said that 386 recent interventional cancer trials in Australia did not include a lot of the major cancers. About 24 were conducted on lung cancer, which is a cancer with the greatest impact of quality of life and life expectancy. Colorectal cancer had 21 trials, even though it is second in terms of life expectancy.

The study found that breast cancer was the most researched type of cancer. The Cancer Council said that clinical research for all types of cancer is necessary in order to find the best way to improve treatment for patients. The council said that lung cancer was the biggest killer and the most easily prevented type of cancer, followed by colorectal cancer. For women, breast cancer is the biggest killer and the third most punishing cancer in terms of healthy life lost.

Some say the study only included registered clinical trials in Australia which did not include unregistered trials. Compulsory registering of trials would allow better research and accurate database in terms of finding out which cancer type research needs further progress. Clinical trials are necessary and are essential in making a difference in survival rates for both men and women.

The report found a significant decrease in cancer death rates for men and women since the early 1990s. However, death rates from liver cancer and melanoma in men, and liver and pancreatic cancer in women continue to increase.

The rate of new cancers, in both men and women, fell on average 1 percent a year, according to data collected. The percentage of prostate cancer cases has increased. Common cancers found in men such as lung, colorectal, oral, stomach and malignant tumors have decreased, while women saw decreases in breast, lung, colorectal, uterus, cervix, bladder and oral cavity cancers.

Unfortunately, pediatric cancer diagnosis have seen an increase in children from birth to 19 years of age.

It is gratifying to see some decline in overall cancer incidence and death rates in the United States. It shows that various methods for preventing, early detection and treatment has significantly improved. The American Association for Cancer Research calls the data remarkable, as it highlights the progress against cancer, and shows that increased knowledge, science, and advances in technology have done a lot to reduce incidence and mortality rates of cancer.

The two companied developed motesanib for patients with non-squamous non-small cell lung cancer. Patients included in the study were receiving either a combination of the drug with chemotherapy or a placebo with chemotherapy. Squamous refers to the type of cancer cells from which the cancer originated.

The patients, as in earlier trials of motesanib, were also more likely to experience serious adverse events more frequently than those with a placebo. Some of the adverse events reported included hypertension and bleeding disorders.

The companies reported disappointment over motesanib failure, but plan to analyze the data closely in order to prepare for further research in the lung cancer area.

In 2008, another study involving the same drug was halted after early data showed higher mortality rates among patients receiving the drug. In 2009, the companies resumed the study with only non-squamous patients, as those patients are more likely to cough up blood during testing. Non-squamous non-small cell lung cancer affects about two-thirds of all non-small lung cancers. The company expected sales of motesanib to reach about $912 million by 2017.